|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||72.51 - 74.38|
|52 Week Range||63.76 - 86.27|
|PE Ratio (TTM)||8.45|
|Earnings Date||Feb 5, 2018 - Feb 9, 2018|
|Forward Dividend & Yield||2.08 (2.86%)|
|1y Target Est||85.70|
Kite, a Gilead Company , announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ in patients with refractory large B-cell lymphoma.
More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday. Yescarta, approved by the U.S. Food and Drug Administration in October for aggressive large B-cell lymphoma that did not respond to other treatments, is part of a new class known as chimeric antigen receptor T-cell therapies, or CAR-Ts, designed to reprogram the body's own immune cells to recognize and attack malignant cells. Follow-up on 108 patients treated with Yescarta showed that 42 percent remained in remission after a median of 15 months, and 56 percent were still alive, according to research presented in Orlando at the annual meeting of the American Society of Hematology.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Gilead Sciences, Inc. Here are 5 ETFs with the largest exposure to GILD-US. Comparing the performance and risk of Gilead Sciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Shares of Gilead Sciences (GILD) are higher Friday, after it announced its acquisition of Cell Design Labs. Kite Pharma, which Gilead bought earlier this year, already owned some 12% of the firm, so Gilead ...
Beleaguered biotech investors will likely have to wait until 2018 to get some much-needed relief, analysts say.
Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.
Drugmaker Gilead Sciences Inc said on Thursday it was acquiring privately-held Cell Design Labs Inc for up to $567 million, giving it access to new technology platforms that would help in the development of cancer drugs. The deal strengthens Gilead's focus on CAR-T drugs, a new class of cancer therapies that involve genetically modifying a patient's own immune cells to better recognize and attack cancer. Gilead said it would make an initial upfront payment to Cell Design of about $175 million and additional payments of up to $322 million upon meeting certain milestones.
Launched little more than a year ago to produce cancer-fighting cell therapies just outside a tumor cell's door, an Emeryville company will be bought by biotech powerhouse Gilead Sciences Inc. for up to $567 million. The technologies behind Cell Design Labs Inc. — born out of the work of University of California, San Francisco, Professor Wendell Lim — could boost the effectiveness of so-called CAR-T drugs while decreasing the risk of potential side effects from those groundbreaking treatments. The buyout is structured with Cell Design Labs getting about $175 million upfront and up to $322 million paid out to most of the company's shareholders after hitting undisclosed milestones.
Gilead Sciences Inc. said late Thursday it will acquire privately held cellular therapy company Cell Design Labs Inc. for $567 million. The company said it will acquire the 12.2% of Cell Design shares ...
Gilead Sciences, Inc. and its cell therapy subsidiary Kite announced today that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms that will enhance research and development efforts in cellular therapy.
–Demonstrates Gilead’ s Deep Commitment to Cell Therapy–. –Novel Cell Engineering Technologies with the Potential to Drive Discovery and Development of New Anti-Cancer Medicines–. –Structured Buy Out to ...
Gilead has a potential GOAT on its hands, an analyst said Wednesday. Its drug, bictegravir, is likely to become the "Greatest Of All Time" among HIV drug launches.
Shares of Gilead Sciences (GILD) are rising Wednesday, helped by a bullish note from Credit Suisse, which argues that its HIV treatment Bictegravir could be a launch that will become "the greatest ...
The University of Houston Graduate College of Social Work is among scientific institutions teaming up to take aim at the growing HIV/AIDS crisis in the southern United States. Gilead Sciences Inc. (GILD), Emory University Rollins School of Public Health, the Southern AIDS Coalition and UH on Dec. 4 announced the Gilead Compass Initiative, a $100 million, 10-year commitment of financial resources and support for organizations working to end HIV/AIDS. The South lags behind other parts of the country in terms of HIV prevention and care indicators, according to the Atlanta-based U.S. Centers for Disease Control and Prevention.
Gilead Sciences, Inc. today announced the launch of the Gilead COMPASS Initiative, a 10-year, $100 million commitment to support organizations working to address the HIV/AIDS epidemic in the Southern United States.
On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.
Stocks are weak out of the gate again, with the tech-heavy Nasdaq down the most. In addition to the tax bill making its way through Congress, we just got the ADP numbers this morning showing private companies added added 190,000 jobs in November. Moody's Mark Zandi warning the job market will be overheated next year. Yahoo Finance's Alexis Christoforous and Jared Blikre discuss.